Cocrystal Pharma, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

COCP$1.11+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(Dollars and shares in thousands, except per share data)

	December 31, 2024	December 31, 2023
Assets
Current assets:
Cash	$9,860	$26,353
Restricted cash	75	75
Tax credit receivable	1,215	890
Prepaid expenses and other current assets	430	1,773
Total current assets	11,580	29,091
Property and equipment, net	153	271
Deposits	29	46
Operating lease right-of-use assets, net (including $152 and $42 to related party)	1,694	1,851
Total assets	$13,456	$31,259
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$2,127	$3,022
Current maturities of operating lease liabilities (including $49 and $42 to related party)	301	240
Total current liabilities	2,428	3,262
Long-term liabilities:
Operating lease liabilities (including $104 and $0 to related party)	1,505	1,613
Total long-term liabilities	1,505	1,613
Total liabilities	3,933	4,875
Commitments and contingencies	-	-
Stockholders’ equity:
Common stock $0.001 par value; 100,000 and 150,000 shares authorized as of December 31, 2024 and 2023, respectively; 10,174 shares issued and outstanding as of December 31, 2024 and 2023, respectively	10	10
Additional paid-in capital	342,931	342,288
Accumulated deficit	(333,418)	(315,914)
Total stockholders’ equity	9,523	26,384
Total liabilities and stockholders’ equity	$13,456	$31,259

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.